Form 4: Neumora Director Matthew Fust Receives Stock Option Grant

Director Matthew K. Fust was granted 80,000 stock options in Neumora Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Matthew K. Fust acquired 80,000 stock options in Neumora Therapeutics, Inc. (NMRA).
• The options have an exercise price of $1.86 per share.
• The grant date for these options is May 27, 2026.
• The options are set to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Performance risk associated with the company's ability to meet clinical or commercial milestones.

Future Outlook

The options vest on the earlier of the one-year anniversary of the grant date or immediately prior to the next Annual Meeting following May 27, 2026.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• Vesting schedules tied to annual meetings are common industry practice to ensure director commitment.

Stakeholder Impact

• Minor potential dilution for existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 27, 2027, or the date of the next Annual Meeting.

Key Dates

Keywords

Neumora Therapeutics, NMRA, Form 4, Insider Trading, Stock Options, Director Compensation